-Reuters
FDA Approves LEQEMBI Under The Accelerated Approval Pathway For The Treatment Of Alzheimer’s Disease
Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™
Treatment with LEQEMBI should be initiated in patients with mild cognitive